WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer Announces Top-Line Results of Third Phase 3 Clinical Trial of Tofacitinib (CP-690,550) 18 April 2011
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease 12 April 2011
Pfizer to Sell Capsugel to KKR 05 April 2011
Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010 01 April 2011
SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation 23 March 2011
Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib 06 March 2011
New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin 13 February 2011
Pfizer To Acquire Ferrosan's Consumer Healthcare Business 07 February 2011
New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan 06 February 2011
Pfizer Reports Fourth-Quarter and Full-Year 2010 Results 01 February 2011
Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc. 31 January 2011
Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older 22 December 2010
Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc. 15 December 2010
Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine 12 December 2010
Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib 06 December 2010
Pfizer Launches Global Centers for Therapeutic Innovation 18 November 2010
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity 15 November 2010
Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent 09 November 2010
Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion 03 November 2010
Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066) 28 October 2010
  • Start
  • Prev
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • Next
  • End
Health data interoperability: Opportunities and threats

Business & Industry

  • Amgen successfully completes acquisition of Five Prime Therapeutics
  • GSK and Vir Biotechnology announce EMA review of dual-action monoclonal antibody VIR-7831 for the early treatment of COVID-19
  • Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
  • Pfizer and BioNTech request regulatory agencies expand emergency use of their COVID-19 vaccine to adolescents
  • Valneva reports positive Phase 1/2 data for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001

Research & Development

  • SARS-CoV-2: New findings on the persistence of neutralizing antibodies
  • Massive fragment screen points way to new SARS-CoV-2 inhibitors
  • B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
  • COVID-19 causes 'unexpected' cellular response in the lungs
  • Clinical trial completion rates decline during COVID-19 pandemic
  • Study identifies possible COVID-19 drugs - including several that are FDA-approved
  • COVID-19 convalescent plasma with greater antibody levels is safe and shows promise

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA revokes emergency use authorization for monoclonal antibody Bamlanivimab
  • Joint CDC and FDA statement on Johnson & Johnson COVID-19 vaccine
  • AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets
  • Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna
  • EMA's safety committee continues investigation of COVID-19 Vaccine AstraZeneca and thromboembolic events
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer completes acquisition of Therachon

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.